This Biotech Attracted a $181 Million Investment During a Staggering 1,300% Stock Rally
This clinical-stage biotech develops small-molecule therapies targeting NASH, obesity, and related metabolic diseases.
📰 Original Source
Read full article at Fool →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.